Trastuzumab deruxtecan, often abbreviated as T-DXd, belongs to a class of treatments known as antibody-drug conjugates, which are sometimes described as guided missiles for cancer cells. The drug pairs a monoclonal antibody that homes in on human epidermal growth factor receptor 2, or HER2, with a potent chemotherapy payload called deruxtecan, attached through a linker designed to remain stable in the bloodstream. Once the antibody binds to its target and the complex is swallowed into the tumor cell, the linker is cleaved and the cytotoxic drug is released. Critically, the payload is membrane-permeable, meaning it can diffuse into neighboring tumor cells that may express little or no HER2 themselves, a phenomenon researchers call the bystander effect. This mechanism explains why the drug works not only in tumors with high HER2 levels but also in the so-called HER2-low category, where the receptor is present at low levels that historically disqualified patients from HER2-targeted therapy.

The concept of HER2-low disease has reshaped how oncologists classify breast cancer. Roughly half of all breast cancers previously labeled HER2-negative actually show weak HER2 expression on immunohistochemistry, and the recognition that these tumors respond to T-DXd effectively created an entirely new treatment category. The pivotal DESTINY-Breast04 trial demonstrated that the drug significantly extended survival in this population compared with standard chemotherapy, leading to approvals in the United States, Europe and elsewhere. But trial populations are often younger, healthier and more ethnically homogeneous than the patients seen in everyday oncology clinics, and questions have lingered about whether the striking trial results translate to routine practice, particularly in Asian patient populations where prior real-world data were scarce.

To address that gap, the Fudan team retrospectively analyzed the medical records of every patient with HER2-low metastatic breast cancer treated with T-DXd at their center during the three-year study window. The cohort was heavily pretreated: the women had received a median of three prior lines of therapy, with some having endured as many as five or more. Their median age was 56 years. About 32 percent had metastatic disease from the moment of diagnosis, known as de novo metastatic cancer, while the remaining 68 percent had developed metastases after an initial diagnosis of earlier-stage disease. Just under two-thirds of the patients had hormone receptor-positive tumors, meaning their cancers were fueled by estrogen or progesterone, while the rest had hormone receptor-negative disease, an aggressive subtype with fewer targeted options.

The headline result was a median real-world progression-free survival, or rwPFS, of 9.1 months, measured from the start of T-DXd treatment until either disease progression or death. For context, the same patients had achieved a median progression-free survival of only 3.5 months on the treatment they received immediately before switching to T-DXd, a descriptive comparison that underscores how much the drug outperformed the therapies that preceded it. Among the 111 patients whose tumors could be radiologically assessed using the RECIST 1.1 criteria, the objective response rate was 30.63 percent, meaning nearly one in three saw their tumors shrink measurably. Add in patients whose disease remained stable, and the disease control rate climbed to 72.07 percent, a remarkable figure for a cohort this heavily pretreated.

Perhaps the most intriguing finding emerged from a subgroup analysis of hormone receptor-positive patients. The researchers discovered that women whose tumors expressed low levels of the progesterone receptor, defined as 10 percent or less of tumor cells staining positive, fared dramatically better on T-DXd than those with high progesterone receptor expression. Their median real-world progression-free survival was 17.77 months, nearly triple the 6.13 months observed in the high-expression group, a difference that was highly statistically significant. The biological explanation remains speculative, but progesterone receptor expression is a marker of a more intact, hormone-driven tumor biology, and tumors with low PR expression may be more genomically unstable and more dependent on cell-kill mechanisms that antibody-drug conjugates exploit. If confirmed, the finding could help oncologists identify which hormone receptor-positive patients are most likely to benefit from early T-DXd treatment.

Taking the analysis a step further, the team built an exploratory prognostic score using multivariable Cox regression, a statistical technique that estimates the independent contribution of multiple clinical factors to survival outcomes. The resulting model, based on age, HER2 status and hormone receptor status, split patients into low-score and high-score groups with strikingly different trajectories: median real-world progression-free survival of 12.4 months in the low-score group versus just 5.13 months in the high-score group. The authors are careful to frame this score as hypothesis-generating rather than a validated clinical tool. Derived from a single-center cohort of 126 patients, it would need to be confirmed in independent, ideally prospective, populations before it could guide treatment sequencing decisions in the clinic. Still, it represents a first step toward personalizing the use of an expensive and sometimes toxic therapy.

The study’s real-world design is both its strength and its limitation. On one hand, it captures the messy complexity of routine clinical care, including patients with poorer performance status, unusual prior treatments and comorbidities that would have excluded them from trials. On the other hand, the retrospective, single-center design means the results are vulnerable to selection bias, and the lack of a control group makes it impossible to draw definitive causal conclusions. The authors also note that detailed safety data, including rates of adverse events such as interstitial lung disease, a known and potentially serious risk of T-DXd, were collected in supplementary analyses rather than forming the primary endpoint. Longer follow-up will be needed to estimate overall survival, which was not yet mature in this cohort.

For patients and clinicians, the significance of the study lies in its confirmation that the extraordinary results seen in clinical trials are reproducible in ordinary practice. T-DXd has already transformed the treatment landscape for HER2-low metastatic breast cancer, offering meaningful extra months of disease control to women who once had little beyond conventional chemotherapy. This new evidence from Shanghai suggests that Chinese patients, who were underrepresented in the pivotal trials, benefit just as substantially, and it hints at biological markers like progesterone receptor expression that could one day refine who receives the drug and when. As antibody-drug conjugates multiply across oncology, studies like this one serve as an essential bridge between the idealized world of clinical research and the real-world clinics where the drugs must ultimately prove their worth.

Subject of Research: Real-world effectiveness of trastuzumab deruxtecan in HER2-low metastatic breast cancer

Article Title: Real-world clinical outcomes of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer

Article References: Zhang, K.-Y., Zhu, X.-Z., Ying, X.-H., Chen, L., & Wang, Z.-H. (2026). Real-world clinical outcomes of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer. BMC Cancer. https://doi.org/10.1186/s12885-026-17096-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17096-7

Keywords: trastuzumab deruxtecan, HER2-low, metastatic breast cancer, antibody-drug conjugate, real-world evidence, progression-free survival, progesterone receptor, RECIST, prognostic score, BMC Cancer, oncology, drug response

The research team set out to answer a deceptively simple question: can the molecular fingerprints of breast tumors be read from two carefully chosen genes, and do those fingerprints tell clinicians anything useful about how a patient’s disease behaves? To find out, they recruited thirty patients with breast cancer and collected paired samples from each one, meaning that for every tumor they also took a sliver of adjacent, apparently normal breast tissue from the same individual. This paired design is powerful because each patient effectively serves as her own control, filtering out the genetic noise that differs from person to person and isolating the changes that cancer itself imposes on the tissue.

The molecular workhorse of the study was quantitative reverse transcription polymerase chain reaction, or qRT-PCR, a technique that amplifies and measures specific RNA sequences with exquisite sensitivity. Using this method, the researchers quantified the levels of miR-199a-3p, a microRNA roughly twenty-two nucleotides long that belongs to a family of short non-coding RNAs known for silencing protein-coding genes after they are transcribed. MicroRNAs do not make proteins themselves; instead, they bind to messenger RNA targets and either degrade them or block their translation, acting as fine-tuning knobs on thousands of cellular pathways. When one of these knobs is broken, entire signaling cascades can swing out of balance, which is why microRNAs have become prime suspects in cancer biology.

The results were striking for miR-199a-3p. In tumor tissue, the microRNA was downregulated to just over half the level seen in the paired normal tissue, a 0.506-fold reduction that reached statistical significance with a P value of 0.0029. In practical terms, this means the difference between tumor and healthy tissue was unlikely to be a fluke of sampling. The finding fits a broader pattern in the literature: miR-199a-3p has previously been shown to suppress migration and invasion of breast cancer cells by dampening the PAK4/MEK/ERK signaling pathway, to enhance sensitivity to cisplatin by downregulating the mitochondrial transcription factor TFAM, and to influence drug responses in triple-negative breast cancer through effects on BRCA1. A tumor suppressor of this kind, when its levels fall, may remove a natural brake on uncontrolled growth.

CDK7 told a more nuanced story. This gene encodes cyclin-dependent kinase 7, a protein that sits at the crossroads of two fundamental cellular processes: it serves as the catalytic heart of the CDK-activating kinase complex, which switches on other cyclin-dependent kinases that drive the cell cycle, and it phosphorylates the tail of RNA polymerase II, the enzyme that transcribes nearly every protein-coding gene in the genome. Because of this dual role, CDK7 inhibitors have attracted intense pharmaceutical interest as potential cancer therapies. Yet in this cohort, CDK7 messenger RNA levels did not differ significantly between tumor and control tissue, with a P value of 0.140. The absence of a bulk expression difference, however, did not render the gene irrelevant.

When the researchers cross-referenced CDK7 expression with the clinicopathological features of each patient’s tumor, a significant association emerged: higher CDK7 expression was linked to progesterone receptor-negative status, with a P value of 0.038. Hormone receptor status is one of the most consequential characteristics of any breast cancer, shaping both prognosis and treatment options, and progesterone receptor-negative tumors are generally more aggressive and less amenable to endocrine therapies. A molecular link between CDK7 and receptor status therefore matters, because it suggests the kinase may participate in the biology that separates indolent tumors from aggressive ones, echoing earlier reports that CDK7 expression correlates with molecular subtypes and clinical outcomes in breast cancer.

Beyond tissue-based measurements, the study also examined CA 15-3, a long-established protein biomarker routinely measured in blood to monitor breast cancer. Serum levels of CA 15-3 were considerably higher in the patients than would be expected in health, a difference that was highly significant with a P value below 0.001. Receiver operating characteristic analysis, a statistical framework that plots sensitivity against specificity across all possible cutoff values, yielded an area under the curve, or AUC, of 0.754 for CA 15-3. At a threshold of 25.1 units per milliliter, the marker achieved a specificity of 96.7 percent, meaning it rarely fired a false alarm, though its sensitivity of 43.3 percent showed it missed more than half of the cancers on its own.

The microRNA and the kinase each carried diagnostic weight as well. miR-199a-3p alone produced an AUC of 0.720, with a 95 percent confidence interval stretching from 0.581 to 0.839, while CDK7 alone managed an AUC of 0.621. Neither was perfect, but the researchers then asked whether combining the two markers into a single model would sharpen the signal. It did. The combined miR-199a-3p/CDK7 model achieved an AUC of 0.750, with a confidence interval of 0.619 to 0.886, and delivered a sensitivity of 76.7 percent alongside a specificity of 80.0 percent. In other words, the two-molecule panel correctly identified more than three-quarters of the cancers while wrongly flagging only one in five healthy samples, a balance that single markers in this study could not match.

These numbers place the findings in a realistic but promising light. An AUC of 0.75 is generally considered to reflect fair to good discriminatory ability, well above the 0.5 that would indicate random guessing, though short of the near-perfect values that would justify immediate clinical deployment. The authors conclude that miR-199a-3p may serve as a possible biomarker for breast cancer diagnosis, characterized by considerably low expression in tumors and moderate diagnostic efficacy on its own, while the combination with CDK7 enhances discrimination and serum CA 15-3 contributes strong specificity. The connection between CDK7 and progesterone receptor status, they argue, further supports the kinase’s therapeutic importance, a claim consistent with the growing pipeline of CDK7 inhibitors now moving through preclinical and clinical evaluation.

The study’s scale invites caution: thirty patients is a modest cohort, and biomarkers that shine in small, single-center studies sometimes fade when tested across larger and more diverse populations. Still, the work from Erbil exemplifies a broader shift in cancer diagnostics, away from reliance on any single molecule and toward multi-marker panels that capture different dimensions of tumor biology. A microRNA that reflects the silencing of tumor-suppressive regulation, a kinase that ties cell cycle control to hormone receptor status, and a serum protein with high specificity together sketch a layered portrait of the disease. If future studies validate these signals in larger cohorts and across breast cancer subtypes, the humble 0.506-fold drop of miR-199a-3p in tumor tissue could become part of a diagnostic toolkit that catches breast cancer earlier and guides treatment more precisely than today’s methods allow.

Subject of Research: Expression of the microRNA miR-199a-3p and the transcriptional kinase CDK7 as diagnostic and clinicopathological biomarkers in breast cancer

Article Title: Association of miR-199a-3p and CDK7 expression with clinicopathological features of breast cancer

Article References: Ibrahim, N. A., & Hidayat, H. J. (2026). Association of miR-199a-3p and CDK7 expression with clinicopathological features of breast cancer. Molecular Biology Reports, 53(1), Article 1650. https://doi.org/10.1007/s11033-026-12831-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12831-6

Keywords: breast cancer, miR-199a-3p, CDK7, biomarkers, qRT-PCR, CA 15-3, progesterone receptor, microRNA, diagnosis, cell cycle, tumor suppressor, Molecular Biology Reports

The clinical backdrop is a striking gap in evidence. Drugs such as palbociclib, ribociclib and abemaciclib, when paired with endocrine therapy, have become the near-universal first-line treatment for this disease, regardless of how strongly a tumour expresses its hormone receptors. Current ASCO and College of American Pathologists guidelines classify a breast cancer as hormone receptor-positive if as little as 1 percent of tumour nuclei stain positive, creating a category so broad it spans tumours that behave like triple-negative disease and tumours that are exquisitely hormone-dependent. Yet the registration trials that established CDK4/6 inhibitors as standard therapy did not stratify their outcomes by oestrogen receptor or progesterone receptor expression levels, leaving clinicians with little guidance on whether a tumour with 5 percent receptor staining responds like one with 95 percent.

PALMARES-2 enrolled consecutive patients with unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who began first-line endocrine therapy plus a CDK4/6 inhibitor after January 2016. At the second data cut-off in January 2025, the study had captured 4,187 patients, of whom 4,115 had quantitative oestrogen receptor data available from pathology reports. The median age was 62 years, most patients had good performance status, and roughly two-thirds had endocrine-sensitive disease. Ribociclib and palbociclib were each used in about 39 percent of patients, with abemaciclib in 22 percent. At a median follow-up of just over 40 months, median real-world progression-free survival for the whole cohort was 25.6 months, and median time to first chemotherapy was 37 months.

The researchers grouped patients by oestrogen receptor expression measured in the most recently available tumour specimen: very high at 90 percent or above, high at 50 to 89 percent, and low-to-intermediate at 1 to 49 percent. The differences in outcome were dramatic. Patients with very high receptor expression enjoyed a median progression-free survival of 28.5 months, those with high expression 20.5 months, and those with low-to-intermediate expression only 10.6 months. After adjusting for age, performance status, histology, progesterone receptor status, HER2 and Ki67 expression, endocrine sensitivity, and sites of metastasis, the hazard ratios confirmed a strong, graded relationship: compared with the low-to-intermediate group, high expression carried a 27 percent lower risk of progression, and very high expression a 46 percent lower risk. A trend test across the ordered categories was highly significant, and the association held in both endocrine-sensitive and endocrine-resistant subgroups.

Progesterone receptor expression added independent prognostic power. Using the well-established 20 percent cut-off that pathologists employ to separate luminal A-like from luminal B-like biology, patients with high progesterone receptor expression had a median progression-free survival of 30.7 months versus 19.2 months for those with low expression, a benefit that persisted in multivariable analysis. Statistically, adding progesterone receptor to models already containing oestrogen receptor significantly improved model fit and discrimination, with Harrell’s C-index rising and formal reclassification metrics confirming the gain. When the two markers were combined, the extremes separated sharply: patients with very high oestrogen receptor and high progesterone receptor tumours achieved a median progression-free survival of 32.4 months and a median time to chemotherapy of 46.4 months, while the 113 patients whose tumours expressed low-to-intermediate oestrogen receptor and low progesterone receptor fared dismally, with a median progression-free survival of just 8.3 months and a median time to chemotherapy of 13.1 months.

Perhaps the most biologically revealing finding concerned the timing of the biopsy. Among 1,408 patients with matched primary and metastatic tumour samples, nearly half — 49.8 percent — changed oestrogen receptor expression category between their original surgery and the diagnosis of advanced disease, reflecting the evolutionary pressure that years of endocrine therapy exert on tumour cells. When the researchers tested whether receptor levels measured in archival primary tumours predicted outcomes on first-line CDK4/6 inhibitor therapy, they found no association. Only receptor levels assessed in fresh biopsies taken at the time of advanced disease diagnosis carried prognostic weight, and a formal statistical interaction between biopsy timing and prognostic value was highly significant. The message is unambiguous: the hormone receptor status that matters is the one the tumour carries today, not the one it carried years ago.

The study also revisited a contentious question in routine oncology: whether the three approved CDK4/6 inhibitors perform equally. After extensive multivariable adjustment and inverse probability of treatment weighting, both ribociclib and abemaciclib outperformed palbociclib on progression-free survival and time to chemotherapy in the overall cohort, confirming and strengthening earlier results from a smaller PALMARES-2 dataset. In the very-high oestrogen receptor subgroup, both ribociclib and abemaciclib beat palbociclib, while in the high-expression subgroup only abemaciclib showed an advantage. In the small low-to-intermediate subgroup, no significant differences emerged, though the authors caution that covariate balance could not be adequately achieved there. These non-randomised comparisons carry residual confounding risks, and they contrast with the recently published P-VERIFY study, which found no differences among the three drugs; the Italian investigators attribute that discrepancy to P-VERIFY’s shorter follow-up and more limited covariate data.

The clinical implications are potentially practice-changing. For patients with strongly hormone-dependent tumours, the excellent outcomes support endocrine therapy plus a CDK4/6 inhibitor as the preferred first-line choice regardless of metastatic site or disease burden, and may even justify less intensive clinical and radiological monitoring. Patients with discordant receptor profiles — very high oestrogen receptor with low progesterone receptor, or low-to-intermediate oestrogen receptor with high progesterone receptor — still benefit but may warrant closer surveillance, particularly when other adverse features are present. For the small group with low-to-intermediate oestrogen receptor and low progesterone receptor tumours, the authors argue that alternative strategies deserve priority, including chemotherapy, antibody-drug conjugates such as trastuzumab deruxtecan, triple combinations adding the PI3K inhibitor inavolisib for PIK3CA-mutated tumours, or enrolment in clinical trials of novel approaches.

The study has limitations that temper, but do not erase, its conclusions. It is retrospective in design, the expression thresholds were chosen partly for convenience, pathology review was not centralised, and genomic data such as ESR1 or PIK3CA mutation status were unavailable. Overall survival analyses remain immature, particularly in the smaller subgroups, and race and ethnicity data were not systematically collected. Even so, the sheer scale of the cohort, the depth of clinical annotation, and the consistency of the signal across sensitivity analyses make a compelling case that quantitative hormone receptor expression — measured in a recent biopsy and read jointly — is one of the most actionable prognostic tools available for this population. If prospective studies confirm the results, routine re-biopsy at metastatic diagnosis and biomarker-guided tailoring of both treatment intensity and monitoring frequency could become standard practice, ending the era in which tumours differing by nearly a hundredfold in receptor expression were treated as a single, undifferentiated category.

Subject of Research: Prognostic value of quantitative oestrogen and progesterone receptor expression in hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line endocrine therapy plus CDK4/6 inhibitors

Article Title: Prognostic value of hormone receptor expression in patients with HR+/HER2− advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study

Article References: Ligorio, F., Provenzano, L., Caputo, R., Vigneri, P., Giuliano, M., Curigliano, G., Toss, A., Botticelli, A., Pedersini, R., Cinieri, S., Lambertini, M., Rizzo, G., Tagliaferri, B., Sirico, M., Giordano, M., Gerratana, L., Meattini, I., Piras, M., Fabi, A., … De Santis, C. (2026). Prognostic value of hormone receptor expression in patients with HR+/HER2− advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study. eClinicalMedicine, 100, Article 104242. https://doi.org/10.1016/j.eclinm.2026.104242

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104242

Keywords: breast cancer, oestrogen receptor, progesterone receptor, CDK4/6 inhibitors, endocrine therapy, PALMARES-2, biomarkers, progression-free survival, real-world evidence, tumour re-biopsy, precision oncology, advanced breast cancer

The research team, led by Chenrui Pan, Bingjie Yang and Huiming Shen as joint first authors under corresponding author Jia Li, focused on contrast-enhanced ultrasound, or CEUS. Unlike conventional ultrasound, which relies on the natural reflectivity of tissues, CEUS injects microbubble contrast agents into the bloodstream. These bubbles, far smaller than red blood cells, course through the tumor’s vasculature and echo sound waves back to the probe, allowing clinicians to watch blood flow through a lesion in real time. Because a tumor’s blood supply is one of the most intimate records of its biology, encoding how it grows, invades and dies, the technique offers a dynamic portrait of tumor physiology that static images cannot match. The researchers asked a deceptively simple question: could the vascular fingerprint of a breast tumor, captured before a single dose of chemotherapy, predict the pattern in which that tumor would later shrink?

To answer it, the team retrospectively analyzed 64 breast cancer patients who underwent neoadjuvant chemotherapy followed by surgery between June 2018 and May 2023 at their institution. After the operations, pathologists examined the removed tissue and sorted the patients into two groups according to their tumor shrinkage pattern, or TSP. Thirty-eight patients, 59.4 percent of the cohort, showed concentric shrinkage, the inward, uniform contraction that leaves a discrete residual tumor border. The remaining 26 patients, 40.6 percent, showed non-concentric shrinkage, the scattered, irregular response that complicates surgical planning. This postoperative pathology served as the ground truth against which the pretreatment imaging and clinical data were tested.

Before treatment began, each patient’s tumor was characterized with both qualitative and quantitative CEUS parameters alongside a panel of clinical features. The quantitative measures included time to peak, abbreviated TTP, which records how quickly the contrast agent reaches its maximum concentration within the lesion, a direct readout of vascular density and perfusion efficiency. The qualitative assessments included the presence of penetrating vessels, arteries that plunge from surrounding tissue into the tumor body and feed its core. The clinical variables spanned the familiar molecular markers of breast oncology: estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, or HER2, the driver protein targeted by some of the most effective drugs in modern breast cancer therapy.

Using univariable and multivariate logistic regression, the researchers distilled this collection of variables down to four independent predictors of the shrinkage pattern: progesterone receptor status, HER2 status, time to peak on contrast-enhanced ultrasound, and the presence of penetrating vessels. Each survived statistical scrutiny with a P value below 0.05, meaning the associations were unlikely to have arisen by chance. The combination is biologically coherent. Hormone receptor and HER2 status define the tumor’s molecular subtype, which shapes how it responds to cytotoxic and targeted drugs. Perfusion kinetics and penetrating vessel architecture, meanwhile, describe the tumor’s plumbing, the delivery network that determines whether chemotherapy reaches every corner of the lesion at lethal concentrations. A tumor with sluggish perfusion or a chaotic, invasive vascular supply may respond in a patchwork fashion, dying here and persisting there, while a well-perfused tumor may contract as a coherent whole.

From these four predictors, the team constructed a nomogram, a graphical scoring tool that assigns weighted points to each variable and sums them into a probability estimate. Such tools are prized in clinical medicine because they translate complex multivariate statistics into something a clinician can use at the bedside. When the researchers tested the nomogram’s discriminatory power using receiver operating characteristic analysis, the results were striking. The area under the curve reached 0.910, with a 95 percent confidence interval of 0.835 to 0.984, placing the model well above the 0.5 threshold of random guessing and into the range considered clinically useful. In practical terms, the tool achieved a sensitivity of 81.6 percent, correctly identifying most patients destined for concentric shrinkage, and a specificity of 88.5 percent, correctly flagging most of those whose tumors would shrink non-concentrically.

The clinical stakes of this prediction are considerable. Breast-conserving surgery, which removes the tumor with a margin of healthy tissue while sparing the rest of the breast, has become the preferred operation for many early-stage patients because it preserves body image and avoids the physical and psychological burden of mastectomy. But when chemotherapy has shrunk a tumor non-concentrically, the residual disease may be scattered in strands and nests far from the original lesion’s apparent border. Operating on the assumption of concentric shrinkage in such a patient risks leaving malignant cells behind, a local recurrence waiting to happen. Conversely, patients whose tumors are predicted to shrink concentrically may be counseled with greater confidence that breast conservation is feasible. A pretreatment forecast of shrinkage pattern gives the surgical team a head start on that conversation, months before the pathology report arrives.

The study’s reliance on pretreatment imaging is what sets it apart from much of the existing literature. Many predictive models in neoadjuvant breast cancer care depend on mid-treatment assessments, requiring clinicians to wait for one or more chemotherapy cycles before imaging can offer guidance. A model built entirely from pretreatment CEUS and baseline clinical features can inform the very first treatment-planning discussion, potentially influencing the choice of surgical strategy, the sequencing of therapy, and even the design of clinical trials that stratify patients by expected response pattern. The technique itself is also widely available and comparatively inexpensive, since contrast-enhanced ultrasound is performed with standard ultrasound equipment and does not involve ionizing radiation, an advantage over repeated CT or MRI-based monitoring.

As with any retrospective study of 64 patients at a single center, the findings require validation in larger, multi-institutional cohorts before they can reshape clinical guidelines. The authors themselves note that the work was approved by the ethics committee of Zhongda Hospital and funded by the Jiangsu Provincial Commission of Health and Family Planning, and the article was published open access on 29 September 2026. Still, the convergence of molecular markers and vascular imaging into a single predictive framework points toward a broader shift in oncology: the idea that the answer to how a tumor will respond is already written into its biology, waiting to be read. With microbubbles, a probe and a well-trained eye, clinicians may soon peer into that biology before the first infusion, and plan surgery around a future they can see coming.

Subject of Research: Predicting breast cancer tumor shrinkage patterns after neoadjuvant chemotherapy using pretreatment contrast-enhanced ultrasound and clinical features

Article Title: Prediction of tumor shrinkage patterns to neoadjuvant chemotherapy based on pretreatment contrast-enhanced ultrasound and clinical features in breast cancer

Article References: Pan, C., Yang, B., Shen, H., Wang, Y., Han, J., & Li, J. (2026). Prediction of tumor shrinkage patterns to neoadjuvant chemotherapy based on pretreatment contrast-enhanced ultrasound and clinical features in breast cancer. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02837-8

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02837-8

Keywords: breast cancer, neoadjuvant chemotherapy, contrast-enhanced ultrasound, tumor shrinkage patterns, breast-conserving surgery, nomogram, HER2, progesterone receptor, time to peak, penetrating vessels, predictive markers, oncology

Endometrial cancer is the most common gynecologic malignancy in developed countries, and its incidence is rising, driven in part by obesity and changing reproductive patterns. For younger patients who hope to preserve their fertility, the standard alternative to hysterectomy is progestin therapy, typically high-dose medroxyprogesterone acetate, which can induce tumor regression and allow pregnancy. The catch is resistance: a substantial fraction of tumors either fail to respond from the outset or relapse after an initial remission, forcing patients toward definitive surgery. Clinicians have long sought molecular clues that predict who will respond and interventions that convert non-responders into responders. The Shinshu team, led by Natsuki Uchiyama and corresponding author Ryoichi Asaka, approached both questions through the lens of tumor metabolism.

ME1 occupies a strategically important position in cellular biochemistry. The enzyme decarboxylates malate to pyruvate while reducing NADP+ to NADPH, a molecule that functions as the cell’s principal reducing currency. NADPH feeds fatty acid and cholesterol synthesis and, critically, powers antioxidant systems such as glutathione reductase that neutralize reactive oxygen species, the chemically aggressive byproducts of aerobic metabolism. Cancer cells, which run biosynthetic pathways at full throttle while enduring metabolic stress, often become dependent on NADPH-generating enzymes. That dependence creates a therapeutic window: inhibit the enzyme, and the tumor cell is caught between a shortage of building blocks and an inability to defuse its own oxidative waste. Until this study, however, ME1’s role in endometrial carcinoma was essentially unmapped.

To chart that map, the researchers performed immunohistochemistry on surgical specimens from 172 patients with endometrioid endometrial carcinoma, alongside six samples of normal endometrium. The staining revealed a clear pattern: ME1 protein was significantly more abundant in tumor tissue than in healthy endometrium. When the team stratified patients by expression intensity, using an H-score threshold of 75.66, they found that tumors with high ME1 were independently associated with shorter progression-free survival, with a hazard ratio of 1.89 and a 95 percent confidence interval of 1.07 to 3.34, reaching statistical significance at P equals 0.028. Because the analysis controlled for other clinical variables, the result suggests ME1 is not merely a passenger marker of aggressive disease but a feature that tracks with, and may contribute to, clinical behavior.

The next step was mechanistic. Working with endometrial cancer cell lines in vitro, the researchers suppressed ME1 two ways: genetically, using small interfering RNA to degrade the enzyme’s messenger RNA, and pharmacologically, using a small-molecule inhibitor. Both approaches curtailed proliferation across every cell line tested, confirming that these cells rely on ME1 for growth. But the most consequential findings emerged in Ishikawa cells, a line that expresses the progesterone receptor, the molecular gatekeeper through which medroxyprogesterone acetate exerts its antiproliferative effects. When ME1 was inhibited in these cells, reactive oxygen species accumulated, and, unexpectedly, the progesterone receptor itself was upregulated. The tumor was, in effect, being re-sensitized to the drug by two complementary routes: oxidative stress pushed it toward the brink, while increased receptor expression gave the progestin more targets to engage.

To quantify how well the two agents worked together, the team applied the Bliss independence model, a standard framework for drug synergy in which a score above zero indicates that the combination outperforms what the individual drugs would achieve additively. The maximum delta-Bliss score reached 0.51, a value indicating strong synergy between ME1 inhibition and medroxyprogesterone acetate. In practical terms, the combination suppressed cell proliferation far more effectively than either treatment alone, and the effect was most pronounced in the progesterone receptor-positive setting where the progestin has a pathway to act. This dual mechanism, ROS accumulation paired with receptor upregulation, offers a coherent explanation for a phenomenon that has puzzled clinicians: why some progesterone receptor-low tumors resist progestin therapy despite otherwise treatable disease.

Cell culture, however, is a simplified world, so the investigators moved to a xenograft model, transplanting endometrial cancer cells into mice and treating the animals with the ME1 inhibitor, medroxyprogesterone acetate, or both. The combination suppressed tumor growth more effectively than either single agent, and, importantly, the treated animals showed no apparent toxicity. That safety signal matters because progestin therapy is chosen precisely to spare young patients the reproductive and surgical consequences of hysterectomy; an add-on drug that imposed heavy side effects would undermine the strategy’s purpose. The in vivo result, while preliminary, suggests that metabolic sensitization could be layered onto existing hormonal regimens without unacceptable cost to the patient.

The study’s implications extend in two directions. As a prognostic tool, ME1 immunohistochemistry could eventually help clinicians stratify patients at diagnosis, identifying those with high-expression tumors who might need closer monitoring or earlier escalation rather than extended courses of progestin that are destined to fail. As a therapeutic target, ME1 inhibition offers a rational combination partner for progestin therapy, potentially converting resistant tumors into responsive ones. The concept fits within a broader movement in oncology that treats metabolic enzymes, once considered housekeeping proteins, as actionable dependencies, a strategy that has already yielded drugs against enzymes in nucleotide synthesis and one-carbon metabolism. ME1’s role in supplying NADPH makes it part of the same family of vulnerabilities.

Caution is warranted before clinical translation. The pharmacological inhibitor used in the study is an experimental tool, not an approved drug, and the xenograft model, though informative, cannot fully reproduce the hormonal and immune environment of the human endometrium. The patient cohort was retrospective, and the survival association, while statistically significant, will need validation in independent and prospective cohorts. Dosing, scheduling, and patient selection for any future combination trial remain open questions, as does the question of whether ME1 inhibition would benefit tumors with low progesterone receptor expression, where the progestin sensitization mechanism may not apply. The authors received no external funding for the work and declare no conflicts of interest, and the study was approved by the ethics committee of Shinshu University School of Medicine.

Even with those caveats, the research delivers a satisfying arc from bench to bedside logic: an enzyme is overexpressed in tumors, its abundance predicts worse outcomes, its suppression stresses cancer cells and raises the very receptor that hormonal therapy depends on, and the combination outperforms either approach alone in living animals. For the growing population of young women facing endometrial cancer who want to preserve their fertility, the prospect of a metabolic drug that makes progestin therapy work more reliably is more than an incremental finding. It reframes treatment resistance not as an immutable property of the tumor but as a metabolic state that can be chemically reversed. Larger trials will decide whether ME1 inhibitors can fulfill that promise, but the Shinshu study has supplied the biological rationale, the prognostic evidence, and the preclinical proof of concept in a single, coherent package.

Subject of Research: Malic enzyme 1 as a prognostic marker and therapeutic target for enhancing progestin sensitivity in endometrioid endometrial carcinoma

Article Title: Malic enzyme 1 is a prognostic factor and a therapeutic target to enhance progestin sensitivity in endometrial cancer

Article References: Uchiyama, N., Asaka, R., Fujioka, M., Kamijo, K., Yokokawa, Y., Shinagawa, M., Nakajima, M., Takeuchi, H., Ando, H., & Miyamoto, T. (2026). Malic enzyme 1 is a prognostic factor and a therapeutic target to enhance progestin sensitivity in endometrial cancer. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06633-3

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06633-3

Keywords: endometrial cancer, malic enzyme 1, ME1, progestin therapy, medroxyprogesterone acetate, progesterone receptor, reactive oxygen species, NADPH, fertility-sparing therapy, tumor metabolism, drug synergy, prognostic marker